MHRA – Page 195 – Pharma.Tips

Residual Solvent Oos during EU/UK market supply: packaging integrity and shelf-life justification

Addressing Residual Solvent OOS During EU/UK Market Supply: Insights into Packaging Integrity and Shelf-Life Justification In the realm of pharmaceutical manufacturing, the detection of a residual solvent Out of Specification…

Ph Drift during method transfer: packaging integrity and CCIT justification

Understanding pH Drift During Method Transfer: Addressing Packaging Integrity and CCIT Justification In the pharmaceutical industry, pH drift during method transfer can lead to significant quality control challenges, particularly for…

Edge Lifting after adhesive change: GMP investigation plan and CAPA

GMP Investigation Plan and CAPA for Edge Lifting Issues Post-Adhesive Change In pharmaceutical manufacturing, particularly within transdermal drug delivery systems, the integrity of adhesive bonds is critical. A common issue…

Dose Delivery Variability in transdermal patch manufacturing: inspection-ready documentation pack

Addressing Dose Delivery Variability in the Manufacturing of Transdermal Patches Dose delivery variability in transdermal patch manufacturing presents significant challenges, often manifesting as deviations or out-of-specification (OOS) results. This article…

Pet Failure during PAI readiness: CAPA and effectiveness check plan

Addressing Pet Failures During PAI Readiness with Effective CAPA Implementation In pharmaceutical manufacturing, particularly with ophthalmic dosage forms, the readiness for a Pre-Approval Inspection (PAI) is critical. One widespread issue…

Packaging Dry-Out during die-cutting: inspection-ready documentation pack

Investigating Packaging Dry-Out Issues during Die-Cutting in Pharmaceutical Manufacturing In the dynamic environment of pharmaceutical manufacturing, particularly in the production of transdermal drug delivery systems, challenges such as packaging dry-out…

Assay Oos after adhesive change: GMP investigation plan and CAPA

Investigation Plan and CAPA for Assay OOS Following Adhesive Change Investigating Out-of-Specification (OOS) assay results after an adhesive change presents a critical challenge in pharmaceutical manufacturing. Such deviations can signify…

Ivpt Failure in transdermal patch manufacturing: GMP investigation plan and CAPA

GMP Investigation Plan and CAPA for Ivpt Failures in Transdermal Patch Manufacturing In the pharmaceutical industry, ensuring consistent product quality is paramount, especially in the manufacturing of transdermal patches. An…

Particulate Matter Oos for multi-dose products: sampling, filtration, and EM controls

Investigating Particulate Matter OOS for Multi-Dose Products: Effective Sampling, Filtration, and Environmental Controls Particulate matter contamination in multi-dose pharmaceutical products, particularly ophthalmic formulations, can pose significant challenges to manufacturers. The…

Ccit Failure during terminal sterilization: FDA/MHRA investigation narrative and batch impact

Examining Ccit Failure During Terminal Sterilization: An In-Depth Investigation Narrative Ccit failure during terminal sterilization poses significant challenges within pharmaceutical manufacturing, potentially leading to batch rejections and regulatory scrutiny. Understanding…

Dose Delivery Variability during EU/UK market supply: inspection-ready documentation pack

Dose Delivery Variability Investigation for EU/UK Market Supply: An Organized Approach Variability in dose delivery can significantly impact therapeutic outcomes and regulatory compliance in pharmaceutical manufacturing. In environments such as…

Ph Drift during bulk hold: cleaning validation and worst-case selection

Investigation of pH Drift during Bulk Hold: Cleaning Validation and Worst-Case Selection pH drift during bulk hold presents significant challenges for pharmaceutical manufacturers, particularly within the realm of topical and…